BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,464,024 | -8.2% | 256,560 | +10.1% | 0.02% | -6.2% |
| Q2 2023 | $19,019,449 | +14.2% | 232,996 | +3.8% | 0.02% | +14.3% |
| Q1 2023 | $16,648,220 | +3.2% | 224,400 | +15.3% | 0.01% | -6.7% |
| Q4 2022 | $16,133,423 | +14.7% | 194,660 | +293.2% | 0.02% | +7.1% |
| Q3 2022 | $14,060,000 | -10.5% | 49,508 | +9.3% | 0.01% | -6.7% |
| Q2 2022 | $15,706,000 | -20.7% | 45,310 | -0.9% | 0.02% | -11.8% |
| Q1 2022 | $19,798,000 | -18.8% | 45,719 | -3.0% | 0.02% | -15.0% |
| Q4 2021 | $24,385,000 | -2.3% | 47,136 | -8.5% | 0.02% | -9.1% |
| Q3 2021 | $24,966,000 | -0.3% | 51,521 | -7.4% | 0.02% | -4.3% |
| Q2 2021 | $25,039,000 | +16.3% | 55,611 | -1.4% | 0.02% | +4.5% |
| Q1 2021 | $21,536,000 | +31.4% | 56,388 | +9.2% | 0.02% | +22.2% |
| Q4 2020 | $16,391,000 | +41.4% | 51,617 | +10.3% | 0.02% | +28.6% |
| Q3 2020 | $11,591,000 | +10.0% | 46,788 | +17.3% | 0.01% | 0.0% |
| Q2 2020 | $10,535,000 | +34.1% | 39,896 | -3.7% | 0.01% | +16.7% |
| Q1 2020 | $7,855,000 | +14.7% | 41,424 | +32.7% | 0.01% | +33.3% |
| Q4 2019 | $6,851,000 | +30.9% | 31,212 | +16.7% | 0.01% | +28.6% |
| Q3 2019 | $5,232,000 | +5.2% | 26,737 | +12.1% | 0.01% | 0.0% |
| Q2 2019 | $4,973,000 | +5.1% | 23,854 | +0.1% | 0.01% | 0.0% |
| Q1 2019 | $4,733,000 | +32.7% | 23,839 | -3.2% | 0.01% | +16.7% |
| Q4 2018 | $3,566,000 | -31.0% | 24,638 | -2.7% | 0.01% | -25.0% |
| Q3 2018 | $5,166,000 | +40.1% | 25,311 | +1.5% | 0.01% | +33.3% |
| Q2 2018 | $3,688,000 | +70.3% | 24,926 | +73.9% | 0.01% | +50.0% |
| Q1 2018 | $2,165,000 | +18.0% | 14,331 | +1.2% | 0.00% | +33.3% |
| Q4 2017 | $1,834,000 | +9.6% | 14,157 | +2.2% | 0.00% | 0.0% |
| Q3 2017 | $1,674,000 | +40.4% | 13,847 | +36.5% | 0.00% | 0.0% |
| Q2 2017 | $1,192,000 | +14.6% | 10,142 | -0.9% | 0.00% | +50.0% |
| Q1 2017 | $1,040,000 | -22.8% | 10,232 | -21.9% | 0.00% | -33.3% |
| Q4 2016 | $1,347,000 | +18.5% | 13,096 | +26.1% | 0.00% | 0.0% |
| Q3 2016 | $1,137,000 | -2.9% | 10,387 | +0.0% | 0.00% | -25.0% |
| Q2 2016 | $1,171,000 | -7.4% | 10,385 | -22.4% | 0.00% | 0.0% |
| Q1 2016 | $1,265,000 | +6.5% | 13,381 | +1.4% | 0.00% | 0.0% |
| Q4 2015 | $1,188,000 | -4.1% | 13,201 | -1.5% | 0.00% | -20.0% |
| Q3 2015 | $1,239,000 | -35.3% | 13,398 | -31.1% | 0.01% | -28.6% |
| Q2 2015 | $1,914,000 | +27.3% | 19,441 | +29.7% | 0.01% | 0.0% |
| Q1 2015 | $1,503,000 | – | 14,985 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |